{"id":"https://openalex.org/W2227239144","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","title":"Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).","display_name":"Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2227239144","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","mag":"2227239144"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.5041","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109056859","display_name":"J. Ang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Ang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T. A. Yap","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. A. Yap","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111319427","display_name":"P. Fong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Fong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110430024","display_name":"C. P. Carden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. P. Carden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071507732","display_name":"Dsp Tan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. S. Tan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078775575","display_name":"Janet Hanwell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Hanwell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109315492","display_name":"J. Carmichael","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Carmichael","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. S. De Bono","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113897043","display_name":"Martin Eric Gore","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. E. Gore","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108195387","display_name":"S. B. Kaye","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. B. Kaye","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"5041","last_page":"5041"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.8799999952316284},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.6620000004768372},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.5189999938011169},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.8059999942779541},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.8349999785423279},{"id":"https://openalex.org/keywords/platinum-resistance","display_name":"platinum resistance","score":0.5239999890327454},{"id":"https://openalex.org/keywords/taxane-resistance","display_name":"taxane resistance","score":0.925000011920929},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.7910000085830688},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.5550000071525574},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9789999723434448},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.906000018119812},{"id":"https://openalex.org/keywords/advanced-ovarian-cancer","display_name":"advanced ovarian cancer","score":0.6029999852180481},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.6190000176429749},{"id":"https://openalex.org/keywords/family-history-of-cancer","display_name":"family history of cancer","score":0.6140000224113464},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.32100000977516174},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.39500001072883606}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9890778064727783},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8811192512512207},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6441134214401245},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6408441662788391},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.6269968748092651},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6178754568099976},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5335543751716614},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4196997582912445},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.41609394550323486},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3552701473236084},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3153747022151947},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.23886319994926453},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.16399472951889038},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.12164261937141418},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06271025538444519},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.5041","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.5041","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2597439582","https://openalex.org/W2147057518","https://openalex.org/W2602036314","https://openalex.org/W1999659306","https://openalex.org/W2199466904","https://openalex.org/W4281899136","https://openalex.org/W2744490258","https://openalex.org/W2243816036","https://openalex.org/W3211335584","https://openalex.org/W4402172662"],"abstract_inverted_index":{"5041":[0],"Background:":[1],"A":[2],"synthetic":[3],"lethal":[4],"approach":[5],"by":[6,171],"PARP":[7],"inhibition":[8],"has":[9],"clinical":[10,56],"activity":[11],"in":[12,285],"BDOC":[13,71],"(NEJM":[14],"2009;":[15],"361:":[16],"123-34).":[17],"Proposed":[18],"mechanisms":[19],"of":[20,26,50,61,108,126,129,135,150,158,197,222,288],"PARPi":[21],"resistance":[22],"include":[23],"the":[24,59,195],"restoration":[25],"BRCA1/2":[27,102],"function,":[28],"with":[29,69,114,137,143,281,294,299],"theoretical":[30],"impact":[31],"both":[32],"on":[33,58,78,118],"platinum":[34],"(PL)":[35],"and":[36,89,94,141,148,164,199,229,238,247,255,283],"taxane":[37],"(TX)":[38],"sensitivities":[39],"(Nature":[40],"2008;":[41],"451:":[42],"1111-5,":[43],"CCR":[44],"2007;":[45],"13:":[46],"7413-20).":[47],"The":[48,191],"aim":[49],"this":[51,286],"study":[52,272],"was":[53,176,201,213],"to":[54,174,224,245],"provide":[55],"data":[57],"use":[60],"CT":[62,74,115,130,200,249],"following":[63,75,116,162,292],"olaparib":[64,79,175,198],"therapy.":[65],"Methods:":[66],"Patients":[67],"(p)":[68],"advanced":[70],"who":[72,263],"received":[73,123,185,264],"disease":[76],"progression":[77,117],"(Apr":[80],"06-Nov":[81],"09;":[82],"doses":[83],"\u2265200mg":[84],"bd)":[85],"were":[86,96,112,232,250],"included.":[87],"Demographic":[88],"clinicopathologic":[90],"factors,":[91],"treatment":[92,293],"details,":[93],"responses":[95,219,223],"documented.":[97],"Results:":[98],"Twenty-six":[99],"p":[100,121,152,184,209,262,291],"(confirmed":[101],"mutations":[103],"[n=22];":[104],"strong":[105],"family":[106],"history":[107],"BRCA1/2-associated":[109],"cancers":[110],"[n=4])":[111],"treated":[113],"olaparib.":[119,225,295],"These":[120],"previously":[122],"a":[124,133],"median":[125,134,192,227],"3":[127,314,317,327],"lines":[128],"(range":[131,139,145,204],"1-10),":[132],"2":[136,315,335],"PL":[138,163],"1-7)":[140],"1":[142,318,329,338],"TX":[144],"1-2);":[146],"58%":[147],"38%":[149],"these":[151,218],"had":[153,267],"previous":[154],"progression-free":[155],"survival":[156,231],"(PFS)":[157],"<6":[159],"months":[160],"(m)":[161],"TX-based":[165,189,248],"CT,":[166],"respectively.":[167,260],"Response":[168],"rate":[169],"(RR)":[170],"RECIST/GCIG":[172],"criteria":[173],"54%":[177],"(95%":[178,215,235,241,252,257],"CI":[179,216,236,242,253,258],"35-73).":[180],"Following":[181],"olaparib,":[182],"most":[183],"carboplatin":[186],"(Cb)":[187],"and/or":[188],"CT.":[190],"interval":[193],"between":[194],"start":[196],"8.7":[202],"m":[203,234,240],"1.2-26.6).":[205],"Of":[206],"23":[207,341],"evaluable":[208],"(Table),":[210],"overall":[211,230],"RR":[212],"43%":[214],"23-64);":[217],"occurred":[220],"independently":[221],"Overall":[226],"PFS":[228],"3.8":[233],"2.1-5.6)":[237],"7.6":[239],"6.2-8.9).":[243],"RRs":[244],"Cb":[246,282],"64%":[251],"35\u201392)":[254],"70%":[256],"42-98),":[259],"Seven":[261],"other":[265],"regimens":[266],"no":[268],"response.":[269],"Conclusions:":[270],"This":[271],"provides":[273],"preliminary":[274],"evidence":[275],"that":[276],"chemoresponsiveness":[277],"is":[278],"maintained,":[279],"particularly":[280],"TX,":[284],"group":[287],"heavily":[289],"pretreated":[290],"Further":[296],"correlative":[297],"work":[298],"additional":[300],"follow-up":[301],"will":[302],"be":[303],"conducted.":[304],"Regimen":[305],"n":[306,309],"(evaluable":[307],"p)":[308],"(responses)":[310],"Cb/liposomal":[311],"doxorubicin":[312],"(LD)":[313],"Cb/gemcitabine":[316],"Weekly":[319,324],"Cb/paclitaxel":[320],"(P)":[321],"5":[322],"4":[323,326,332],"P":[325],"Docetaxel":[328],"0":[330,333,336,339],"LD":[331],"Topotecan":[334],"5-FU/doxorubicin":[337],"Total":[340],"10":[342],"Author":[343],"Disclosure":[344],"Employment":[345],"or":[346,350],"Leadership":[347],"Position":[348],"Consultant":[349],"Advisory":[351],"Role":[352],"Stock":[353],"Ownership":[354],"Honoraria":[355],"Research":[356],"Funding":[357],"Expert":[358],"Testimony":[359],"Other":[360],"Remuneration":[361],"AstraZeneca":[362,363,364,365,366]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}